Abstract | Several important lessons have been learnt from our experiences in screening for various cancers. Screening programmes for cervical and colorectal cancers have had the greatest success, probably because these cancers are relatively homogenous, slow-growing, and have identifiable precursors that can be detected and removed; however, identifying the true obligate precursors of invasive disease remains a challenge. With regard to screening for breast cancer and for prostate cancer, which focus on early detection of invasive cancer, preferential detection of slower-growing, localized cancers has occurred, which has led to concerns about overdiagnosis and overtreatment; programmes for early detection of invasive lung cancers are emerging, and have faced similar challenges. A crucial consideration in screening for breast, prostate, and lung cancers is their remarkable phenotypic heterogeneity, ranging from indolent to highly aggressive. Efforts have been made to address the limitations of cancer-screening programmes, providing an opportunity for cross-disciplinary learning and further advancement of the science. Current innovations are aimed at identifying the individuals who are most likely to benefit from screening, increasing the yield of consequential cancers on screening and biopsy, and using molecular tests to improve our understanding of disease biology and to tailor treatment. We discuss each of these concepts and outline a dynamic framework for continuous improvements in the field of cancer screening.
The proximate goal of cancer screening is the identi fication of early stage cancer, or precancerous lesions, before a person develops symptoms and at a point in the disease trajectory when treatment is likely to result in cure. This concept is simple, but practicing effective screening on a population level is a complex endeavour. In 1968, Wilson and Jungner 1 of the WHO proposed cri teria that should be met before a screening test should be implemented
; these principles continue to guide policy in countries where implementation of organized screening programmes is being considered. For a number of common cancers, some of these cri teria have been met; however, many continue to present challenges and remain incompletely addressed
Wilson and Jungner's suggestion that "the natural his tory of the condition, including development from latent to declared disease, should be adequately understood" (REF. 1 ) seems particularly prophetic. At the time of the WHO report, and for decades after, the prevailing model of carcino genesis was that of a linear progression from precursor disease to early stage (localized) cancer and, subsequently, to advancedstage (disseminated) cancer.
Indeed, the models of colorectal cancer (CRC) tumori genesis proposed by Vogelstein et al. 2 in the late1980s suggested a relatively slow, stereotyped evolution from colonic polyp to cancer, commensurate with the acquisi tion of certain mutations over time. A similar paradigm has become established for the natural history of cervi cal cancer, and healthcare organizations in a number of countries, including the USA, introduced screening for breast and prostate cancers, presuming that these diseases also followed this classic developmental framework.
With mass implementation of screening for cancer, our experiences on the population level have deep ened our understanding of cancer biology. Screening efforts have revealed a previously unappreciated reservoir of precancerous lesions and indolent cancers that would not have otherwise come to clinical attention. By con trast, other cancers have been recognized to grow so fast that screening assessments performed at predetermined intervals do not enable detection before their spread to local or distant organs. Indeed, we now understand that 'cancer' comprises a heterogeneous collection of dis eases, both across and within organ sites. The advent of geneexpression profiling and other molecular diagnos tic methodologies has advanced our understanding of cancer biology beyond the original model proposed by Vogelstein and colleagues. In fact, treatment decisions are increasingly being guided by gene expression profiling, rather than by traditional factors, such as disease stage or histopathological features 3 . The challenge in screening for and prevention of disease relates to the concept that it is difficult to make healthy people better off than they already are, but not as difficult to make them worse off. Screening, by virtue of increasing the likelihood of performing a biopsy, will potentially uncover a reservoir of biologi cally moreindolent cancers, some of which might lack the potential to progress to meta static disease (the ulti mate cause of most cancerrelated deaths). Detection of indolent lesions is not intrinsically harmful, but can lead to downstream diagnostic and therapeutic inter ventions that cause serious adverse effects to patients. Nevertheless, screening can be of benefit when diagnosis and treatment of a precancerous lesion or an early stage tumour will avert progression of disease to metastasis and/or death. This hope continues to form the basis for population screening for cancer, but also fuels the hype that surrounds cancer screening.
Going forward, lessons learned from the careful distillation of several decades of experience in cancer screening can guide practice and drive improvements in cancer screening. Four key lessons and their corollaries form the foundations for this Review of screening for breast, prostate, cervical, colorectal, and lung cancers
. These concepts serve to refine -rather than replace -the Wilson and Jungner criteria, by highlight ing the corresponding action points that must be con sidered to continue improving the delivery of screening assessments. We present a framework for improving cancer screening, based on a stepwise examination of the decisions that must be made before, during, and after deployment of a screening test. Owing to the scope of this topic, emerging technological advancements in screening tests are discussed where relevant, but are not otherwise comprehensively covered.
Screening: a population-based view Cancer screening can contribute to decreasing cancer morbidity and mortality through two mechanisms: the detection of a precursor lesion, or the early detection of invasive cancer. The benefits of screening are greater when the detection of disease at an earlier (or precancer ous) stage improves outcomes; therefore, the available treatment should be safe, acceptable, and more effective when implemented earlier in the disease course.
The identification of true precursor lesions through population screening should result in a decrease in the incidence rates of invasive cancer over time. Colonoscopy and colposcopy (following cervical cytol ogy) enable direct visualization of the target organs (rectum and colon, and cervix, respectively), and con current or subsequent removal of atrisk tissue. The use of these approaches depletes the reservoir of precancer ous lesions, namely colonic polyps and cervical intra epithelial neoplasia (CIN), which has led to a decrease in the overall incidence of the respective invasive cancers 4 (FIG. 1). The success of populationbased screening pro grammes using cervical cytology in reducing the inci dence and mortality rates of invasive cervical cancer fuelled enthusiasm surrounding screening for other (pre)cancers. The detection and removal of all sus pected precursor lesions, however, does not lead to the same result in all screening programmes. As is discussed herein, widespread use of mammography screening has increased the frequency of intervention to remove in situ breast lesions, but has not resulted in a decline in the incidence of invasive breast cancer 5, 6 . The under lying biology and heterogeneity of cancers largely deter mine the tradeoff between the benefits and the harms of screening.
Differences in disease biology between cancers of the same organ site are of particular importance for tests aimed at the early detection of invasive cancer. Such tests rely on either radiographic imaging of a target organ (for example, mammography for breast cancer and lowdose computed tomography (LDCT) for lung cancer), or measurement of a circulating biomarker associated with presence of the disease (for instance, PSA testing for prostate cancer). These tests are benefi cial when they detect invasive cancer at an early, local ized stage. The desired effect is a 'stage shift' , whereby the proportion of patients diagnosed with early stage disease increases over time, accompanied by a decline in incidence of advancedstage disease -reflecting averted progression of cancers via early detection and treatment. Importantly, the absolute decrease in the incidence rate of advancedstage disease should be considered, rather than the change in the relative pro portions of these cancers versus earlystage disease, as the latter comparison can be falsely reassuring if an excess of early stage cancers that would not other wise progress to advanced stages is detected through screening 7 . Additionally, one must consider whether the stage shift is associated with an improvement in disease related mortality, or because this measure is also affected by the efficacy of treatment, the incidence of metastatic cancers 8 .
Key points
• Tumours within any organ site can have a spectrum of biological phenotypes, ranging from indolent to highly aggressive • Screening for cancer is most likely to be beneficial when the target tumour type has a relatively uniform biology and a slower rate of progression • Not all precursor lesions are on an obligate pathway towards invasive-cancer development • Strategies for early detection of cancer must balance the benefits of mortality reduction (and reduction in invasive-disease incidence with screening for precancers) with the heterogeneity of the target disease and the consequent risk of overdiagnosis • Screening can be viewed as a 'cascade' involving multiple steps, such as selection of individuals to be screened, administration of the screening test, workup of positive findings, and, ultimately, treatment • Efforts are underway to individualize decision-making surrounding risk stratification, the modality and frequency of screening, and diagnostic and therapeutic interventions tailored to the biology of the detected tumour
The focusing of screening programmes on the early detection of invasive cancer arose from an incomplete understanding of the heterogeneity in cancer biology. Cancers can have a spectrum of clinical behaviours, ran ging from indolent to aggressive. At one end of this spectrum lies a subset of cancers so aggressive that screening will not, ultimately, be of benefit. This subset comprises cancers that are prone to early systemic spread and, therefore, have a poor prognosis 8 . Despite routine screening, patients with these cancers will already have distant metastatic disease at the time of detection. The term 'interval cancer' is commonly applied to sympto matic tumours that arise in between screening intervals. These cancers tend to be more aggressive and are diag nosed at more advanced stages than screendetected lesions 9 . Representing more of a limitation of screen ing, rather than a harm, patients with interval cancers present with clinical symptoms, and at the same disease stages, regardless of screening. Moreover, in clinical studies, these clinically detected cancers are associated with a worse prognosis than those detected as a result of screening 10 , thus challenging the paradigm that screen ing is effective at improving patient outcomes for all tumour phenotypes.
Screening predominantly detects lesions other than interval cancers, which necessarily include tumours with slow and moderate growth velocities. A difficult challenge, therefore, is to avoid preferential detec tion of indolent (slowgrowing) cancers that might not otherwise come to clinical attention; detection of these cancers might increase the incidence of early stage cancers, but is unlikely to substantially reduce the incidence of advancedstage cancers because they would probably never progress to such a stage during the patient's lifetime. Herein lies a potential harm of screen ing: in addition to the intrinsic risk of falsenegative and falsepositive results owing to the imperfect sensitivity and specificity of the screening tests, screening incurs 'overdiagnosis' , defined as the detection of cancerous lesions that would not have caused morbidity or mor tality. A closely related concept is 'overdetection' -the detection of premalignant lesions that are not destined to progress to malignancy. Patients with premalignant lesions and indolent cancers can be subjected to invasive tests and treatments, or toxic therapies; therefore, the theoretical risks of overdetection can be similar to those of overdiagnosis: 'overtreatment' . Overtreatment refers to therapy that is inappropriately invasive or extensive in relation to the biology of disease and can occur with a variety of diseases.
Overdiagnosis has been observed on the popula tion level since the 1990s, when screening of children for neuroblastoma was associated with this effect 11 ; however, a particularly illustrative example is that of thyroidcancer screening in the Republic of Korea (South Korea). Widespread governmentsponsored screening in South Korea led to a fivefold increase in the incidence of papillary thyroid cancers without a concomitant decrease in diseasespecific mortality 12 . Organized populationscreening for thyroid cancer does not exist in the USA, although the incidence rate of thyroid cancer is increasing most rapidly of all cancers, owing largely to opportunistic ultrasonography screening 13, 14 . The uncovering of a large reservoir of indolent thy roid cancers illustrates the potential for overdiagnosis when screening is targeted at cancer types with a large reservoir of nonprogressive disease (BOX 2: Lesson 1). Similarly, not all precancerous lesions are obligate pre cursors of invasive disease (BOX 2: Lesson 2). As will be explained in the following sections, populationwide trends, such as those seen for thyroid cancer in the Republic of Korea, can provide valuable clues as to whether screening is having unintended consequences (BOX 2: Lesson 3). In these instances, screening exposes a large population of healthy people to unnecessary harms (BOX 2: Lesson 4). Specifically, overdiagnosis leads to subsequent diagnostic and therapeutic inter ventions that carry risks, but are ultimately of limited or no benefit (overtreatment).
Thus, screening is likely to be of limited benefit at either extreme of cancer aggressiveness. The challenge is to leverage the experience with screening on the popu lation level gained to date, to continue advancing our understanding of cancer biology, in order to avoid over diagnosis and overtreatment. In the following sections, we review the two major populationbased screening strategies, detection of precursor lesions and early detec tion of invasive cancer, to further illustrate the lessons and corollaries outlined in BOX 2. 
Detection of precursor lesions
Cervicalcancer screening was adopted based largely on the results of early observational studies that showed a decrease in incidence of the disease coincident with widespread screening 15, 16 . Randomized clinical trials (RCTs) performed in India subsequently revealed a mortality benefit of cervicalcancerscreening pro grammes [17] [18] [19] . Moreover, high usage of cytologybased screening in US women has been accompanied by a decline in cervicalcancer incidence and mortality (FIG. 1) . The causal link between screening and reduced cervicalcancer mortality is also supported by the obser vation that over half of the incident cervical cancer cases reported each year in the USA and other countries occur in the relatively small subpopulation of unscreened women 20, 21 . Of note, cervicalcancer risk can be entirely eliminated among women who undergo total hysterec tomy; the high prevalence of hysterectomy by the age of 65 years among women in the USA -up to 50% -has contributed heavily to the observed low rates of cervical cancer in this population 22 . The benefits of screening colonoscopy have largely been extrapolated from the results of RCTs of sigmoid oscopy, and from findings of observational studies that demonstrated a reduction in CRC incidence and mor tality rates in participants who received colon oscopy [23] [24] [25] . The data from RCTs of sigmoidoscopybased screening, although differing in the number and frequency of assess ments, endoscopic equipment used, and trial design, indi cate that this approach is associated with reductions in CRC incidence rate by 18-23% and in disease specific mortality by 22-31% 26 . Of note, the reductions in the incidence rate and mortality were only statistically sig nificant for distal cancers 25 , leading to the hypothesis that regular screening with colonoscopy would enable detection of as many distal cancers and more proxi mal cancers than screening with sigmoidoscopy, given the ability of colonoscopy to enable visualization of the colon proximal to the splenic flexure. Indeed, findings of two early multicentre trials on onetime colonoscopy screening for asymptomatic individuals indicated that sigmoidoscopy alone might result in a substantial bur den of highrisk lesions being missed, as approximately 50% of these advancedstage neoplasms occurred in the proximal colon and were not associated with distal ade nomas 27, 28 . To date, no completed trial has directly com pared the efficacy of sigmoidoscopy and colonoscopy, but pooled analyses of data from cohort studies on colon oscopy have revealed decreases in CRC incidence and mortality related to proximal and distal cancers 25 . These findings mirror the population decline in CRC incidence and mortality since the 1980s (FIG. 1) ; the sharpest decline in incidence rates occurs after 2000, when data from the above multicentre colonoscopy trials spurred increased uptake of colonoscopy screening. Colonoscopy every 10 years is considered by some experts to be the most favourable screening strategy, given its sensitivity, ability to detect serrated polyps, and longlasting protection against future CRC 29 ; however, other CRC screening strategies have also been shown to be effective, including sigmoidoscopy every 5 years and/or yearly stoolbased testing with faecal immunohistochemical or faecal occult blood tests 30 . Simulation models have estimated that the cumulative effect of the various CRC screening strat egies is responsible for 50% of the observed decline in incidence and mortality rates of this disease in the USA 31 . Screening for cervical cancer and CRC capitalizes on the typically slow, stereotyped progression that lesions comprising atypical cervical cells and colonic polyps undergo during their transformation into malignant neoplasms. The discovery of human papillomavirus (HPV) as the aetiological driver of most cervical cancers prompted further change in the approach to screening for this disease to incorporate consideration of HPV infection status and adjust future interventions accord ingly 32 . Cervical cells infected by oncogenic strains of HPV can sometimes develop into CIN, which can pro gress to cervical cancer if left untreated 33 . Similarly, some colonic polyps progress to malignancy after acquiring genetic mutations, which differ based on the histologi cal type of the polyp; for example, investigators have demonstrated that hyperplastic polyps and tubulovillous polyps have distinct mutagenesis pathways 34 . The lead time for such transitions spans several years, allowing adequate time for detection and treatment of the polyp before it becomes malignant. The findings regarding the biology of these diseases, and the experience in screening for them demonstrated that screening is most likely to be beneficial when the targeted cancer has a relatively uniform biology and a slower rate of progression
Lesson 1, corollary).
Another important lesson learned is that not all pre cancerous lesions are obligate precursors to invasive cancers; in fact, most are not
Lesson 2). Even in the absence of screening and removal, many cases of CIN do not progress to cervical cancer -the immune system often clears HPV infections associated with CIN grade 1, and 40% of CIN grade 2 lesions spontan eously regress 32, 35 . Similarly, most colonic polyps will not transform into invasive neoplasms, and a substantial The biology of invasive cancers ranges from indolent to aggressive Corollary: Screening will be of greatest benefit if targeted at detecting progressive, potentially morbid disease while avoiding identification, and/or reflexive treatment, of indolent disease Lesson 2: Not all precancerous lesions are obligate precursors of invasive cancers; in fact, most are not Corollary: Treatment of precancerous lesions is of greatest benefit when it prevents potentially morbid disease, or otherwise removes precursors of less-aggressive disease in an effective, nontoxic way Lesson 3a: Effective screening and removal of early stage cancers should cause a concomitant decline in the incidence of advanced-stage cancers Lesson 3b: Effective screening and removal of precursor lesions should cause a concomitant decline in the incidence of invasive cancers Corollary: Population-level trends can be analysed to identify unintended consequences of screening, such as overdiagnosis, and drive efforts aimed at improving outcomes
Lesson 4:
Not all individuals will benefit equally from screening Corollary: Screening should be offered to a carefully defined target population after consideration of risk factors and overall prognosis proportion -perhaps 30% -of small (<6-9 mm) polyps will regress, as suggested by findings of CTcolonography surveillance of unresected polyps 36 . Thus, many resected CIN lesions and colonic polyps would not have otherwise caused morbidity or death. Identification and removal of such lesions represents overdetection and overtreat ment, respectively. Treatments for both of these lesion types are generally considered minimally invasive; never theless, they have inherent risks. Polypectomy to remove colonic polyps can rarely be complicated by bleeding or colonic perforation 37 , and colonoscopy can commonly lead to abdominal pain and bloating 38 . Excisional treat ments for cervical lesions, such as loop excision and cone biopsy, carry risks, including bleeding and infection, and have been linked to adverse obstetrical outcomes, such as preterm birth 39 . Treatment harms are difficult to prove with certainty, and the increased risk of preterm birth among women who undergo the mostcommon cervical excisional technique (loop excision) has been called into question 40 . Nonetheless, current management guidelines recommend restraint in using excisional procedures for the treatment of cervical neoplasia in young women to avoid potential longterm health consequences associated with preterm birth.
Such risks, although not trivial, are generally toler ated because excisional treatments for CIN and colonic polyps are considered effective at preventing the devel opment of invasive cancers, and are less toxic than the treatments that would otherwise be required if the dis eases progressed to this stage (BOX 2: Lesson 2, corollary). Additionally, this practice is probably the predominant reason for the observed decline in the incidence of CRC and cervical cancers in the countries where screening is widespread (BOX 2: Lesson 3b). Tailoring the frequency of screening and limiting intervention for lesions that are not believed to be precursors to morbid disease, how ever, have been key challenges in screening aimed at prevention of these cancers. In guidelines published in 2012, the United States Preventive Services Task Force (USPSTF) recommend increasing the age of initiation of cervical screening cytology from 18 to 21 years, extend ing screening intervals, and implementing an upper age limit of 65 years for screening of women with prior nega tive test results 32 , reflective of a deeper understanding of the underlying biology of cervical neoplasia
Lesson 4).
On the other hand, the management of ductal carci noma in situ (DCIS) of the breast has been the subject of heavy scrutiny precisely because current treatment strat egies are not satisfying the corollary of Lesson 2
: treatment itself is associated with some risks, especially considering that the risk of progression and death for certain types of DCIS and invasive disease is quite low. The incidence of DCIS in the USA increased more than 500% between the early 1980s and late 1990s, largely paralleling the advent of screening mammography, and has stayed relatively constant since then 41, 42 . That many cases of DCIS do not progress to invasive breast cancer is widely acknowledged; nevertheless, the standard therapy over the past 25 years or more has been surgical resec tion (mastectomy, or lumpectomy plus adjuvant radio therapy) and hormonal therapy 6, 43 . Despite treatment of >60,000 DCIS cases per year in the USA, the incidence of invasive breast cancer has not fallen 42 ; moreover, breastcancer mortality has been unaffected by wide spread treatment of DCIS (BOX 2: Lesson 3a) 44 . The nat ural history of DCIS is largely unknown, as most DCIS lesions are surgically resected. According to the available data, the prevalence of invasive cancer in the setting of DCIS might range from 0-50% 45, 46 . Notably, the biol ogy of the lesion dictates the risk of associated invasive cancer, with highgrade comedotype DCIS having a higher likelihood of coincident invasive cancer 47 . Highgrade comedo and lowgrade noncomedo DCIS are increasingly recognized to represent distinct disease entities, with the latter probably constituting overdiagnosis. Lowgrade DCIS, even if untreated, is unlikely to cause breastcancerspecific mortality: a recent study reported 10year survival of 98.8% for women with untreated lowgrade DCIS, and 98.6% for those in whom lowgrade DCIS was surgically excised 48 . For lowgrade DCIS, the risk might be spread over the woman's lifetime, whereas for high grade DCIS, it might be concentrated within 5 years 46 . Indeed, highgrade DCIS is morecommonly associated . Approximate eras of widespread use of the respective screening tests are represented by black lines, with dotted regions representing initial periods of increasing dissemination of the tests following their introduction. The incidence rates of cervical cancer in women and colorectal cancers in both men and women have declined since the early-to-mid 1980s, probably owing to the screening-based detection and subsequent removal of cervical intraepithelial neoplasia and colonic polyps, respectively. On the other hand, the incidence rates of prostate cancer and breast cancer have increased over the same timeframe, probably owing to increased detection of localized cancers as a result of the widespread use of prostate-specific antigen (PSA)-based and mammography screening, respectively.
with local recurrence after treatment, distant metastasis, and mortality, and could be considered a true precursor lesion 49, 50 . Consideration of DCIS grade alone, however, is unlikely to be sufficient in determining the risk of invasive cancer, and could potentially continue to result in overdiagnosis. In the past 3 years, a gene expression profiling test has been introduced as a tool to delineate DCIS biology 45 . In addition, profiling of the tumour immune micro environment might provide insights into the aetiology of, and inform treatment approaches for, the highest risk DCIS lesions 51 .
Early detection/stage shift
Screening approaches aimed at early detection of inva sive cancer have been shown to reduce cancerrelated mortality rates in some large RCTs with longterm fol low up; however, considerable controversy remains over optimal use of the screening tests, and regarding how to balance the benefits and the harms of over diagnosis and subsequent overtreatment, especi ally in settings outside of closely monitored clinical trials. For example, mammographybased screening was shown to reduce breastcancerrelated mortality in early RCTs [52] [53] [54] , although morerecently available longterm followup data from completed trials have provided conflicting information on whether mammography decreases breastcancer mortality 55, 56 . Of note, mammography trials have varied in key aspects, such as screening frequency and technique, randomization scheme, and attribution of outcome 57 . In meta analyses of screen ing trials, investigators have reported a decrease in diseasespecific mortality associated with screening for breast cancer of approximately 20%, although the mortality reduction varies by age 57, 58 : the absolute mortality reduction at 10 years is greatest in women aged 60-69 years (21 deaths per 10,000 women), and lowest in those aged 40-49 years (3 deaths per 10,000 women) 59 . At the population level, breastcancer mortality in the USA has declined since 1990 (REF. 13 ). Despite some uncertainty, this decline is probably attributable to the combined effects of screening and therapy, and might be dominated by the unquestioned improvements in systemic therapy for locallyadvanced and node positive breast tumours over the past two decades 60 . Microsimulations have yielded a very broad range of estimates for the contribution of screening to the decline in mortality observed in the USA (28-65%) 61 . The mag nitudes of these estimates vary dramatically because simulations are influenced by the assumptions and inputs on which each model is based. In fact, even the lower bound estimate might be optimistic. As systemic treatments improve, the mortality reduction attributa ble to screening diminishes, and accurate modelling of the dissemination of new therapies, or the magnitude of their effects, can be difficult 60 . Likewise, accounting for overdiagnosis and lengthtime bias in models is challenging, leading to overestimation of the benefits of screening 62 . This consideration is important because 22-31% of breast cancers detected on mammography are estimated to represent overdiagnosis 63 . Thus, two points relevant to screening can be made with the example of breast cancer. First, the mortality reduction attributable to screening diminishes as sys temic treatments improve. Notably, most of the screen ing mammography trials were conducted before the advent of modern adjuvant treatment for breast cancer. Second, a reservoir of indolent disease exists that is detected with screening. After the widespread imple mentation of mammographic screening in the USA in the midtolate 1980s, the overall incidence of invasive breast cancer increased substantially, and remains sub stantially higher than rates before screening 7 (FIG. 1) .
This increased incidence largely reflects detection of a greater number of localized (early stage) tumours, accompanied by a disproportionately small decrease in latestage cancers 7 , and whether this trend translates to lowering of diseaserelated mortality is controversial. Interestingly, an ecological study showed no reduction in breastcancerspecific mortality in regions of the USA with the highest uptake of mammographic screening 64 .
In the face of such complexity, the differing inter pretation of the evidence by several guidelineissuing professional bodies around the world is perhaps unsur prising (TABLE 1) . In updated guidelines published in February 2016, the USPSTF continued to recommend screening mammography every 2 years for women aged 50-74 years, and that women aged 40-49 years should only be offered screening based on individual circum stances related to patient preferences 65 . These recom mendations were based, in part, on a decision analysis 66 and systematic reviews 59, 67 commissioned by the USPSTF. In 2015, the American Cancer Society (ACS) modified their guidelines for breastcancer screening, based on a separate systematic review 58 , and their recommendations now more closely resemble the USPSTF guidelines, with the exception of recommended annual screening for women between the ages of 45 and 54 years 68 . American breastimaging societies and the American College of Obstetrics and Gynecology (ACOG) continue to recommend annual screening beginning at the age of 40 years 69, 70 , whereas European countries recommend screening every 2-3 years, with starting ages that range between 40 and 50 years [71] [72] [73] . A similar picture is seen with screening for prostate cancer. Death from prostate cancer has also declined since the 1990s 13 , and this reduction is probably at least partially attributable to screening 74 . In the USA, the incidence of prostate cancer presenting initially as metastatic disease has decreased since the advent of PSAbased screening, indicating that screening and subsequent intervention does avert the progression of some localized tumours 8 . Nevertheless, two major RCTs of PSAbased screening produced discrepant findings related to prostatecancerspecific mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) study investigators reported no benefit 75 , whereas the European Randomized Study of Screening for Prostate Cancer (ERSPC) investigators reported a 21% reduction in the relative risk of prostatecancerspecific mortality 76 . Differences in the study designs and populations, as well as the relatively high proportions of men in the control groups who underwent PSAbased screening, might explain these conflicting results 77 . Regardless, the poten tial for overdiagnosis, with subsequent overtreatment, is widely recognized as a major downside of PSAbased screening. Indeed, a substantial increase in the incidence of prostate cancer has been observed following the dis semination of PSAbased screening (FIG. 1) , mostly driven by early stage tumours with a low Gleason score 7 . Many lowgrade prostate cancers will not invade beyond the prostatic capsule during the man's lifetime 78 , and thus subsequent biopsies, resections, and/or radi ation therapy expose the patient to unnecessary harms. Additionally, a normal serum PSA level (typically below 4 ng/ml) does not exclude the possibility of prostate cancer: in the Prostate Cancer Prevention Trial 79 , 42.4% of all cancers with Gleason score ≥7 occurred in men with PSA val ues of ≤3 ng/ml. In the face of an unfavourable riskto benefit ratio, the USPSTF has now recommended against the routine use of PSAbased screening, and to date, no country has introduced a national PSAbased screening programme 80, 81 . Other major professional soci eties, how ever, urge shared decisionmaking regarding PSAbased screening. For example, the ACS recommends that this discussion should begin at the age of 50 years for men at average risk 82 , whereas the American Urological Association (AUA) recommends consideration of screen ing in men aged 55-69 years 83 . Similarly to the ACS, the European Association of Urology (EAU) recommends that PSA testing should be offered to men over 50 years of age (or earlier in certain risk groups, such as men with a family history of prostate cancer), and can continue until the individual's life expectancy is less than 15 years 84 . Lung cancer screening with LDCT has garnered increased attention based on results of the National Lung Screening Trial (NLST) 85, 86 . In this study, 53,454 adults deemed to be at high risk of lung cancer on the basis of age and smoking history were randomly assigned to undergo three annual screenings with either LDCT or chest radiography 85, 86 . After a median followup duration of 6.5 years, the LDCT arm had three fewer deaths per 1,000 individuals screened than the radi ography arm -a 16% reduction in the relative risk of lung cancerspecific mortality 86, 87 . An excess of 120 lung cancers was detected by LDCT versus radiography, however. With the use of modelling to account for life time follow up, the overdiagnosis rate for screening with LDCT was estimated to be 11% overall, but was nearly 50% for bronchioloalveolar cell carcinoma and only 3% for other cell types 88 . The use of LDCT was also associ ated a cumulative falsepositive rate of 37% owing to the detection of benign pulmonary nodules that share ima ging characteristics with lung cancer 85 . Results of a retro spective ana lysis of the NLST data, however, indicate that application of the LungRADS reporting system, developed by the American College of Radiology, could potentially reduce the falsepositive rate and overdiag nosis 89 . Findings of the Dutch-Belgian NELSON trial 90 of screening for lung cancer with LDCT at 2year inter vals after the initial screen indicated improved specificity compared with annual screening in the NLST 85 A concern is that the efficacy of LDCT seen in the clinical trial setting will not translate into effectiveness in community practice; some of the success in the NLST might be due to the high level of expertise in LDCT interpretation and patient management at the partici pating medical centres, 76% of which were National Cancer Institute (NCI)designated cancer centres 91 . Nevertheless, in the USA, screening for lung cancer is currently recommended for former or current smokers with a 30 packyear history of tobacco use (and a quit date within 15 years for former smokers) by the USPSTF and other professional societies [92] [93] [94] . Beginning screening at the age 55 years is generally advocated, but the recom mended age at which to end screening varies between the guidelines 94 . The careful delineation of the candidates for LDCT based screening illustrates an understanding that not all individuals benefit equally from screening
Lesson 4). The prevailing lesson learned from current experience in screening of lung, breast, and prostate cancers, however, is that these cancers are truly hetero geneous in terms of their biological phenotype
Lesson 1). If the corollary of this lesson is not heeded, screening will disproportionately detect slower grow ing cancers and has the potential to reveal a reservoir of more indolent disease. Given the clear excess of early stage cancers detected with populationlevel screening for breast and prostate cancers, room for improvement of these programmes clearly exists (BOX 2: Lesson 3a). Screening can lead to overdiagnosis and overtreatment if the potential for the detection of indolent cancers is not recognized and treatment decisionmaking does not account for disease biology. Geneexpression profiling of breast tumours, for example, has revealed a wide array of phenotypic features associated with differences in aggressiveness, and has begun to highlight the important interaction between biological phenotype and approaches to treatment [95] [96] [97] .
Tempering hype: an eye on improvement The perception and message surrounding screening for cancer has evolved to acknowledge the complex inter play of risks and benefits inherent to its practice. Hype around screening initially centred around the sound bite that 'early detection saves lives' -an intuitive, power ful message, attractive to practitioners and patients alike. Early campaigns promoting the use of screening tests, such as mammography and colonoscopy, prom inently featured (and in some cases, inflated) the pur ported benefits, while neglecting the potential harms 98 . Widereaching population screening was initiated at a time when the linear model of cancer progression prevailed. Reports from cancer registries showed that patients with early stage cancers had goodtoexcellent outcomes, and those with advancedstage disease had much higher mortality rates. This observation led to the belief that detecting cancer at an early stage would uniformly reduce cancerrelated mortality; however, this framework did not account for the extensive bio logical complexity and heterogeneity in cancer, which we are increasingly recognizing, or the associated vari ability in disease progression. Thus, the nearly uniform enthusiasm for screening contributed to a lowvalue, or 'more is better' , approach to screening 99 . Admittedly, conceptualizing the rewards from less screening is dif ficult, and the lay public, based on decades of public health messaging, tend to overestimate the benefits and underestimate the harms of screening 100 . Findings suggest that the concept of overdiagnosis, a clear harm that can be incurred in healthy, asymptomatic people, is discussed relatively infrequently between patients and healthcare providers 101 . A guiding principle of cancer prevention and screen ing is that making healthy people better off than they already are is difficult. Prasad et al. 102 have argued that no clear evidence indicates that any of the current cancer screening protocols convincingly reduce all cause mortality, except LDCTbased screening for lung cancer -and even then, raise the possibility that the reduction in allcause mortality in the NLST might be smaller than reported. The downstream harms of over diagnosis and overtreatment probably dilute or even nullify disease related benefits of cancer screening in general, and exposure to such harms is more difficult to justify in the healthy population than in the man agement of patients with symptomatic disease. The frequency of screening should, therefore, be optimized based on detection of the tumour types for which bene ficial outcomes of intervention are most likely. Those patients with tumours that progress too fast will not benefit from moreintensive screening, which would, however, increase the rates of falsepositive findings and overdiagnosis on the population level.
In Europe, such harms are ameliorated, to some extent, by the centralized approach to screening; pro grammes are organized with fixed budgets, and with formal consideration of the tradeoffs, as opposed to the opportunistic approach used in the USA. In each setting, the same data are viewed and interpreted through different metaphorical lenses -relating to, for example, the financing and organization of health care, malpractice litigation and cultural attitudes toward risk, interventions, and the politics behind the 'war on cancer' . In Europe, such considerations have led to the generally moreconservative approach to the dissemi nation of screening. Consider breastcancer screening, for example: each European nation follows one guide line, and screening of women is usually recommended to begin at 50 years of age, occur every other year, and end at the age of 65-70 years (TABLE 1) . Currently, no organized populationscreening programmes for lung or prostate cancer are active in Europe. Moreover, government based screening in European nations affords several additional benefits. Firstly, comprehen sive regis tries of screening outcomes are assembled. Secondly, quality measures can be better implemented, which probably explains the lower recall rates and higher cancertobiopsy ratios reported in Europe compared with the USA. Factors relevant to the latter advantage include the minimum requirement for mam mogram reads (960 every 2 years in the USA compared with 5,000 per year in Denmark and the UK); double reading (having two radiologists review each image); and the centralization of reading, possibly making mammograms easier to compare, with an emphasis on high specificity [103] [104] [105] . Nevertheless, important efforts are emerging in the USA to acknowledge the limitations and tackle the knowledge gaps with regard to cancer screening. These efforts have brought about renewed hope that screening programmes will meet the hype that initially accompanied them. First of all, increased awareness of overdiagnosis has prompted major professional groups to revise their guidelines 68, 106 . Furthermore, the NCI convened a working group on overdiagnosis, which made several key recommendations to guide practice and research 107 . The American College of Physicians has also focused attention on highvalue care in cancer screening 99, 108 . Moreover, increased coverage in the press and other laypublications in response to these actions has helped disseminate the screening debate among the general public.
Taking the key lessons learned from past experience and their corollaries
, we can formulate corre sponding action points to improve cancerscreening efforts. In the face of a heterogeneous disease biology
Lesson 1), efforts should be made to identify the true 'targets' of screening -namely, better defining a positive test result based on molecular phenotyping of lesions. Given the uncertainty regarding whether all precursor lesions are predecessors to clinically con sequential disease
Lesson 2), a prevention or riskreduction strategy, rather than treatment inter vention, should be considered as the initial approach for some of these lesions. Considering the heterogeneity of risk in the population (BOX 2: Lesson 3), risk strati fication might better identify the individuals who are most likely to benefit from screening. Populationbased data on screening outcomes should be compiled into regis tries to provide continued feedback and thus enable quality improvement (BOX 2: Lesson 4). Lastly, similarly to treatment, screening should be based on both prog nostic and predictive diagnostics, informed by a bet ter understanding of disease phenotype, with a goal of characterizing and correlating screening abnormalities with the specific type of cancer biology using emerging prognostic and predictive tools. We posit that progress is being made across all five of these goals, with evi dence of application and progress across all of the five cancers that are key targets for screening (that is, those of the breast, prostate, lung, cervix, and colon/rectum).
We have integrated the lessons learned with the screening 'cascade' proposed by Harris et al. 109 to illus trate how tailored innovations are being incorporated at each step of the screening process (FIG. 2) . We believe that such innovations set the stage for 'precision screen ing' , which incorporates individualized riskprediction, based on clinical factors and biomarkers integrated with molecular characterization of the cancers detected. This approach should improve elucidation of the targets for cancer screening and prevention. Individualized data and patient values should be taken into account when making key decisions on whom to screen, when to initiate and cease screening, how often to screen, and what action to take for patients with abnormal findings. Efforts are already well underway to generate the infor mation that will enable us to harness this knowledge to improve screening. The 'output' generated at each step of the screening cascade is linked with valuable oppor tunities for continued improvement. We have sum marized the tools that will facilitate improvements in screening practices
.
Precision along the screening cascade
Persons who are screened Initiation of screening has to be undertaken acknow ledging that "overdiagnosis exists and is common," which is one of five recommendations made by an NCIsponsored thinktank working group on over diagnosis 107 . The decision to screen should factor in an individual's pretest probability of cancer, a threshold risk level at which testing is most likely to have a net benefit, and patient values and attitudes towards risk tolerance. Risk stratification has been practiced in a rudimentary form since the advent of screening, as the cumulative risk of nearly all cancers increases with age; therefore, minimum ages at which to begin screening in individ uals at lowtoaverage risk have been recommended -be it faecal occult blood testing, sigmoidoscopy, or colonoscopy at the age of 50 years, or cervical cytology at 21 years of age. Differences in interpretation of the available evidence, however, continue to spur disagree ment over these age thresholds 110 . Additionally, the pres ence of familial risk syndromes or a concurrent disease state associated with an elevated cancer risk places an individual in a highrisk group, warranting considera tion of earlier and morefrequent screening. Examples include hereditary nonpolyposis colorectal syndromes 111 or inflammatory bowel disease 112, 113 and CRC risk. Beyond age and conditions associated with an increased risk of malignancy, exposure history is increas ingly considered in riskstratification. For example, given the robust, dosedependent association between cigarette smoking and lung cancer, the NLST investiga tors selectively enrolled participants who met a mini mum of 30 packyears of smoking history and, if former smokers, had quit less than 15 years before study entry 85 . Most screening guidelines and reimbursement criteria for lungcancer screening reflect the parti cipant demo graphics of the NLST, namely limiting use of LDCT to people with a minimum smoking history of 30 pack years 92, 114 . Similar riskstratification tools have been developed for CRC screening 115 and lungcancer screening 116 , and their clinical utility is currently being studied. Newer proposed algorithms for cervicalcancer screening suggest that HPV testing alone can identify a lowrisk population (those with a negative test result), or that typespecific testing of HPV types 16 and/or 18 might help to further refine riskstratification, such that women with evidence of oncogenic HPV types should have morediligent evaluation 117, 118 . Riskprediction models are increasingly being used for riskstratification. The Breast Cancer Risk Assessment Tool, one of the earliest risk prediction tools, . Our recommendations for cancer-screening programmes focus on incorporation of key clinical questions at each step of the cascade, as well as components of the 'feedback loop' (areas to refine) -aspects of screening decision-making that can be actively improved using outcomes from the corresponding step on the cascade. IDLE, indolent lesions of epithelial origin.
was developed to identify women for inclusion in trials of preventive interventions for breast cancer, and considers exposure to endogenous hormones, in addition to other clinical risk factors 119 . Other risk prediction models are targeted at individuals suspected of having familial breast cancer 120, 121 . The Breast Cancer Surveillance Consortium (BCSC) riskprediction tool incorporates age, race, fam ily history, mammographic breast density, history of prior breast biopsy (and type of benign breast disease, if present) to calculate a woman's 5year and 10year risks of developing breast cancer 122, 123 . Beyond risk factors commonly incorporated in prediction models, some specific exposures clearly identify women at risk (for example, history of mantle radiation), and these women are recommended to undergo annual screening with MRI and mammography 124 . In addition, biomarkers have been combined with riskprediction tools in the hope of improving their performance. A polygenic risk score based on 76 single nucleotide polymorphisms (SNPs) has been shown to independently predict breast cancer risk, and improved riskprediction when incor porated into the existing BCSC model 125 . To date, more than 90 SNPs have been associated with breastcancer risk 126 , and incorporation of additional SNPs might fur ther enhance the predictive value of the polygenic risk score. In the upcoming WISDOM trial 127 , investigators will use the BCSC model, genetic mutation analysis, and a SNP panel to estimate the 5year breastcancer risk score of the women enrolled and, ultimately, assign them a tailored plan, personalizing the starting age, stopping age, and frequency of screening -all within the bounds of the USPSTF guidelines at study initi ation. Over time, the risk model will be refined, as will screeningtest assignment 127 .
The screening test
Screening should follow another of the goals raised at the NCIsponsored thinktank: to "mitigate over diagnosis by testing strategies that lower the chance of detecting unimportant lesions" (REF. 107 ). One can pursue this within three domains, as discussed in the following sections.
Choice of screening test. Imaging tests serve to local ize lesions and provide visual clues about the likeli hood of malignancy and aggressiveness. With regard to prostatecancer screening, following up detection of an elevated PSA level with prostate MRI can help to rule out a falsepositive result, and if a lesion is present, to improve the yield of tumour tissue upon biopsy 128 . Women at very high risk of breast cancer, such as BRCAmutation carriers, firstdegree relatives of BRCAmutation carriers, or those with a 20-25% lifetime risk according to prediction models, should be screened annually with MRI, as an adjunct to mam mography, given the superior sensitivity of MRI in this population 124, [129] [130] [131] . Conversely, use of less invasive or costly strategies is a possibility for individuals on the other end of the risk spectrum. For example, less frequent screening might be appropriate for individu als considered to be at 'very low' to 'low' risk of CRC according to the prediction model discussed in the prev ious section 115 . Of note, all current cervical screen ing guidelines by the ACS, USPSTF, and ACOG incor porate HPV testing as an alternative to cytologyonly strategies 108 .
Frequency of screening. The frequency of testing is a question that has long been central to quality improvement efforts in cervicalcancer and CRC screen ing. In both scenarios, results of the first test or previous tests are used to inform decisions about how and when to repeat screening. In cervicalcancer screening, a com bination of a normal cytologytest result and a test result showing no evidence of infection with highrisk (onco genic) HPV types among women aged ≥30 years pre dicts a particularly low risk of CIN and invasive cancer 33 ; a 5year screening interval is currently recommended for these women 32 . Women with evidence of infection with oncogenic HPV types can have morediligent evalu ation, whereas those with nononcogenic HPV infections can be followed less intensively 117, 118 . Likewise, the absence of colonic polyps on colonos copy (and even the presence of small polyps that lack concerning histological features) is associated with a low risk of CRC development over the next decade, and the next screen can, therefore, occur in 10 years 132 . Breastdensity measurements obtained from initial mammograms (breast imagingreporting and data sys tem (BIRADS) density) has been strongly linked to breastcancer risk; for example, extremely dense breasts in the setting of elevated risk, such as a family history of breast cancer, or in a woman aged 40-49 years support annual (rather than biennial) screening with mammog raphy 133 . In the Stockholm3 (STHLM3 trial) 134 , a base line PSA threshold of 1 ng/ml informed the frequency of prostate cancer screening: if a parti cipant had a PSA level <1 ng/ml, he was not recommended to undergo screening during the following 6 years.
Definition of a positive test result. Experience with pre cursor lesions has shown that not every 'positive' result warrants further immediate investigation or a biopsy. Historically, the standard of care for young women with abnormal cytology was followup colposcopy; however, newer screening approaches integrate watchful waiting (active surveillance). The 2012 management guidelines of the American Society for Colposcopy and Cervical Pathology 135 , for example, recommend that women aged 21-24 years with minimally abnormal cytological findings be followed with annual cytology testing, as many such lesions regress spontaneously. Incorporating strict criteria for embarking on a clinical workup into the screening cascade is important. Active surveillance, which will be covered in detail in the next section, can be used for individuals with indeterminate lesions, or those that probably represent indolent disease or its precursors. Additionally, according to the Lung RADS reporting criteria, pulmonary nodules <6 mm in diameter detected on an initial LDCT screen do not constitute a 'positive' result given they do not require intervention, or necessitate changes to the screening frequency or modality 136 . This example illustrates an important concept, and one that is applicable to any screening study: a 'finding' does not necessarily consti tute a 'positive' result. Lastly, results from the STHLM3 trial 134 indicate that combining information on PSA levels, SNP genotype, circulating protein markers, and clinical variables can improve the accuracy of detection for prostate cancers with a Gleason score of ≥7. This demonstration that the STHLM3 model outperformed PSA testing alone for detection of these highrisk pros tate cancers might usher in an era in which screening tests have more narrowlydefined targets related to clinically consequential cancers 134 .
The clinical workup
The aim of a clinical workup in an individual with a positive screeningtest result is to establish a patho logical diagnosis of cancer or highrisk neoplasia, and gather the data necessary for precision treatment. In many cases, a positive result will trigger an invasive diagnostic test, for example, an imageguided biopsy for a suspicious breast mass detected on mammography. In addition to standard pathological review for histol ogy, extent of disease, and tumour markers, increasing options are available for molecular characterization of tumours. Geneexpressionprofiling tests have been developed to enable prediction of recurrence risk after treatment for invasive cancers and to support treatment decisions. Notable examples are the Oncotype DX® and MammaPrint® assays for geneexpression profiling of breast cancers 95, 96 . Further refinements to these tests, such as establishment of an 'indolent threshold' for the MammaPrint® 70gene signature 137 , have enabled identification of a particularly indolent form of the disease. These advances have enabled geneexpression profiling to be performed on biopsy samples of screen detected tumours to facilitate riskstratification and thus prevent overtreatment.
Molecular profiling has changed the view that a standard treatment is uniformly beneficial for all inva sive cancers. Approximately onethird of breast cancers detected using modern screening modalities are defined as 'ultralow risk' based on geneexpression profiling 138 . These cancers are associated with no risk of breast cancer related death in the first 15 years after surgical treatment and a <5% risk of late breastcancerrelated death (17-20 years after surgical treatment) with a short course of tamoxifen 137 . Certainly, identification of a precursor of this kind of indolent cancer has no rationale. Lowhistologicalgrade DCIS, as defined by pathologists, is probably a risk factor for the develop ment of such indolent cancers, and this disease entity closely matches the definition of indolent lesions of epithelial origin, or 'IDLE' conditions, that was pro posed by the working group convened by the NCI 107 . Other candidate IDLE conditions include the subset of indolent lung cancers identified within the NLST and Gleason 3 + 3 prostate cancers 107 . Setting up observa tional registries for IDLE conditions will enrich our understanding of the natural history of these tumours and provide guidance on how to incorporate informa tion on disease dynamics (that is, whether the tumours progress, remain stable, or regress) into individualized management approaches. These efforts would parallel the NCI working group's recommendation of creating observational registries for IDLE conditions 107 . This approach has already been shown to hold promise with regard to lungcancer screening. The rollout of LDCT occurred in an era when the risks associated with screening and subsequent diagnostic testing were recognized, and as such, quality measures were formulated to standardize the clinical workup. For example, the LungRADS tool can be used to guide the management of nodules detected on LDCT 136 : on the basis of size, appearance, and growth rate, nod ules are assigned a probability of malignancy using this tool, as well as a recommended timeframe and modality for surveillance. This strategy limits unnecessary ima ging (only nodules larger than 6 mm, or 4 mm if new, require followup assessment) and tissue sampling, which is reserved for 'Category 4B and 4X' lesions, such as >1.5 cm solid nodules 136 . Likewise, the investigators of the NELSON study used strictly defined criteria for a 'positive' test result based on nodule volume or volumedoubling time, which probably improved the positive predictive value of LDCT (40.4%, 95% CI 35.9-44.7%), compared with the performance of this modal ity reported in other studies, such as the NLST (3.8%, 95% CI 3.4-4.3%) 85, 90 . The observation that CIN grade 2 lesions have a high spontaneous regression rate has led to recommenda tions that these lesions be followed, rather than treated, especi ally in young women in whom treatments might lead to adverse reproductive outcomes 135 . Repeating col poscopy with cytology at 6month intervals is specifi cally recommended for women aged 21-24 years, but can be offered to women of any age with CIN grade 2 in whom the harms of treatment are believed to outweigh the benefits 135 .
Treatment
A comprehensive discussion of cancer therapy is out side the scope of this Review, but tailored therapy is discussed briefly, in the context of limiting overtreat ment of indolent tumours. Geneexpression profiling has deepened our understanding of the range of disease entities that are currently classified as 'cancer' based on the classic criteria of histological appearance. In the cases with diagnostic test results that suggest indolent disease, lessaggressive therapies should be pursued. For instance, lowgrade DCIS is more likely to be an indicator for an increased risk of future invasive cancer, similarly to its closely related pathological entity atypi cal ductal hyperplasia 46 , rather than an indication for immediate surgery and radiation therapy; a potentially better alternative is to consider these lesions as an oppor tunity for prevention, using selective oestrogenreceptor modulators or aromatase inhibitors. Thus, for certain women with breast lesions, endocrine therapy alone might be sufficient 96, 137 . Moreover, if the workup reveals an IDLE tumour, consideration should be given to active surveillance. When appropriate, changing the nomenclature of IDLE lesions, to reflect their typically benign clinical course, will help frame the decision between patients and pro viders. The NCIsponsored thinktank members rec ommended removing terms related to 'cancer' -as has been instituted for some CIN grade 3 lesions, formerly known as carcinoma in situ 107 . A consortium of seven centres (funded by grants from the NCI) are working together to identify common biological criteria for indolent cancers and IDLE conditions, to help redefine ' cancer' in the era of modern molecular medicine 139 .
Systems-level improvements
Across the entire screening cascade, several advance ments have the potential to improve screening pro grammes. For example, outcomes registries can support continued improvement by providing realtime feed back. National cancer registries have long been a main stay in Europe, and have provided an opportunity for detailed cohort studies on screening outcomes 140, 141 . In the USA, morelimited registries, such as the Breast Cancer Screening Consortium 142 , have linked data from regional mammography registries to form a represent ative sample of the country. The American College of Radiology's lungcancerscreening registry represents a burgeoning attempt to form a national screening registry with an aim towards quality improvement 143 . The ultimate goals of this and similar ventures are to promote evidencebased practices (such as manage ment of incidental findings) and improve reporting in order to enable continued assessment of screening practices. Participation in this registry enables screen ing centres to meet the qualityreporting require ments mandated by the Centers for Medicare and Medicaid Services 143 .
One key knowledge gap is centred on screening in the elderly and particularly those with considerable comorbidities -demographics in which few clinical trials of screening interventions have been conducted. Screening should proceed cautiously in the elderly, frail population; for example, many smokers aged within the 55-74 year range who represent the target for LDCT screening for lung cancer, based on the NLST results 85, 87 , have concurrent cardiac or pulmonary disease that will limit their lifespan. Across the screening cascade, ideally, the individual's underlying comorbidities and frailty should be incorporated into decisionmaking on the riskbenefit tradeoff. One such example of this approach is provided by ePrognosis, a prediction tool that is available online (http://eprognosis.ucsf.edu/) and as a smartphone application, and can be used to guide cancer screening in the elderly. The tool juxtaposes the predicted mortality benefit from screening with competing risks, based on a synthesis of published geriatric risk indices 144 . Integration of such tools into screening decisions is a promising area of future research, and the development of a tool that could be applied widely across all screening indications should be a research priority.
Finally, engaging individuals through shared decision making and the routine offer of participation in studies should be major goals. Many decision tools have been created to facilitate discussions around screening, and tackle the complex interplay between risks, benefits, and each individual's preferences 145 . Patientoriented studies, such as the WISDOM trial 127 , are probing the feasibility and acceptability of precision screening, and should provide critically needed data and key insights. Moreover, the Centers for Medicare and Medicaid Services has mandated that a "lung cancer screening counselling and shared decision making visit" must occur before a LDCT scan being ordered, and is a requirement for reimburse ment, emphasizing the need to consider patient preferences 143 . Patient preference could have an important role at the points in the screening cascade at which a biopsy or treatment is recommended. If potentially morbid disease is unlikely to be present, or the suspected lesion is thought to be associated with low mortality, then such uncertain ties should be communicated to the patient. Patients' values and levels of risk tolerance can help direct decision making: those intolerant of the risks of a potential malig nancy might favour an aggressive approach and, therefore, intervention, whereas others might favour a watchful waiting approach. Those in the latter group should be cau tioned of the potential need for more frequent diagnostic testing, and the associated risks and benefits.
Conclusions
We now recognize that cancer encompasses a hetero geneous collection of conditions, and approaches to screening are changing accordingly. Opportunities for improvement are demonstrated by advancements in each of the screening programmes for lung, breast, prostate, colorectal, and cervical cancers, and can inform efforts to further advance the state of the art of screening. Learning who is at risk of which cancers, in terms of both site and biology, will be a critical underpinning for improvements in screening. The tools required to conduct studies to elucidate these data are coming online, owing to our increasing understanding of the genetic and biological basis of cancer risk, as well as the immunotypes, geno types, and phenotypes of the tumours that arise. Herein, we have assembled the lessons learned from screening for five major cancers (breast, lung, prostate, cervical, and colorectal cancers; BOX 2) into a quality framework to accelerate our ability to introduce precision screening (FIG. 2) , tailored to biology, patient preference, and clinical performance status.
